Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7741 to 7755 of 8314 results

  1. Patient access schemes and pricing agreements

    Home What NICE does {"@context":"http://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"item":{"@id":"/"

  2. Compliance with nice-approved medicines or treatments

    Clarification on demonstrating patient access to medicines and treatments recommended by NICE Technology Appraisal (TA) or Highly Specialised Technologies (HST) guidance.

  3. Focusing on what matters most to the NHS

    For more than 25 years NICE has helped practitioners and commissioners get the best care to people, fast, while ensuring value for the taxpayer.

  4. Highly specialised technologies evaluation committee members

    Biographies for each member of the highly specialised technologies evaluation committee.

  5. Technology appraisal committee D members

    Find out more about NICE technology appraisals advisory committee D members

  6. Prioritising our guidance topics

    Our centralised approach to prioritising our guidance topics ensures that we produce guidance that's relevant, timely, accessible, and has demonstrable impact.

  7. Prioritisation board decisions 2024

    Our centralised approach to prioritising guidance topics ensures that we produce guidance that is relevant, timely, accessible, and has demonstrable impact.

  8. Our prioritisation decisions

    NICE's decisions on how we prioritise topics, by year.

  9. Preparing for the next breakthroughs in liver disease treatments

    With no licensed treatments for MASH, a serious liver condition affecting 3 million in the UK, NICE has co-developed a framework with patients, clinicians, and industry to accelerate access to promising new medicines.

  10. NICE's backing of the prostate cancer drug abiraterone could help thousands and save the NHS millions

    Our landmark review demonstrates a new approach to keeping NHS care up-to-date and could benefit thousands of adults with metastatic prostate cancer.

  11. NICE to stop supplying print copies of BNF and BNFC

    To support use of up-to-date content, and drive sustainability and digital transformation, the upcoming editions of BNF and BNFC (scheduled for distribution in October and November 2023) will be the last print editions to be supplied to the NHS in England by NICE.

  12. About quality standards

    Our quality standards set out priority areas for quality improvement in health, public health and social care.

  13. Artificial intelligence (AI) and digital regulations service

    We're playing a leading role in the AI and digital regulations service which supports the development and adoption of AI and data-driven technologies in health and care.

  14. Technology appraisal and highly specialised technologies appeals

    Learn about the NICE Technology Appraisal and Highly Specialised Technologies appeals process, including how decisions are made, the criteria for appeals, and the role of the appeal panel in ensuring fair and transparent evaluations of health technologies.

  15. Up to 6,000 people set to benefit after NICE recommends new life-extending drug for advanced prostate cancer

    People living with metastatic prostate cancer in England will gain access to a new treatment combination from today (Friday, 24 October), following a recommendation by NICE.